Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Prosthetic valve endocarditis after transcatheter aortic valve implantation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Left ventricular thrombus in multisystem inflammatory syndrome in children associated with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis. Prosthetic valve endocarditis (PVE) after TAVI is a serious complication, but only limited data exist on its incidence, outcome, and procedural risk factors.

METHODS AND RESULTS: Observational single-center study of 509 consecutive patients treated with a transcatheter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve). We identified 18 patients diagnosed with TAVI-PVE during a median follow-up period of 1.4 years (interquartile range, 0.5-2.5 years; longest follow-up was 6.3 years). TAVI-PVE was most frequent in the first year after implantation (first-year incidence, 3.1% [confidence interval, 1.4%-4.8%]); the overall annualized rate was 2.1% per patient-year (confidence interval, 1.2%-3.3%). Seventeen patients (94%) were treated conservatively and 1 with surgery. Four patients (22%) died from endocarditis or complications to treatment, 2 of those (11%) during initial hospitalization for PVE. An increased risk of TAVI-PVE was seen in patients with low implanted valve position (hazard ratio, 2.8 [1.1-7.2]), moderate or worse postprocedural paravalvular regurgitation (hazard ratio, 4.0 [1.5-11]), implantation of >1 prosthesis (hazard ratio, 5.2 [1.5-18]), and any vascular complication (hazard ratio, 3.8 [1.5-9.8]).

CONCLUSIONS: TAVI-PVE occurred at a slightly higher rate than reported for surgically implanted valves. Conservative treatment was associated with an acceptable outcome. Suboptimal valve deployment and vascular complications were associated with an increased risk of TAVI-PVE.

Original languageEnglish
JournalCirculation. Cardiovascular interventions
Volume8
Issue number4
Pages (from-to)e001939
ISSN1941-7640
DOIs
Publication statusPublished - Apr 2015

    Research areas

  • Aged, Aged, 80 and over, Aortic Valve Stenosis, Denmark, Endocarditis, Non-Infective, Female, Follow-Up Studies, Heart Valve Prosthesis, Humans, Incidence, Male, Postoperative Complications, Risk Factors, Survival Analysis, Transcatheter Aortic Valve Replacement, Treatment Outcome

ID: 46172662